All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2021
Details:
The new data demonstrate that in vivo base editing of the PCSK9 gene in the liver of non-human primates resulted in durable and consistent lowering of blood LDL-C and blood PCSK9 protein levels following a single course of treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SIG-005
Therapeutic Area: Genetic Disease Product Name: SIG-005
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
SIG-005 contains a human cell line genetically modified with a non-viral vector designed to express human a-L-iduronidase (IDUA), an enzyme which is missing or defective in patients with MPS-1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-based gene therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 16, 2020
Details:
Proceeds will accelerate clinical development of multiple gene therapy programs, novel gene therapy product designs, next generation technology platform and state-of-the-art AAV Vector GMP manufacturing capabilities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GPH101
Therapeutic Area: Genetic Disease Product Name: GPH101
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
GPH101 harnesses the power of CRISPR and natural DNA repair mechanisms to precisely insert the correct DNA sequence, with the aim of directly correcting the disease-causing sickle mutation and leading to the production of normal red blood cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBGM01
Therapeutic Area: Genetic Disease Product Name: PBGM01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
This is the first regulatory authorization for the global PBGM01 clinical trial program, the Imagine-1 study, for the treatment of infantile GM1, a rare and often life-threatening CNS disorder with no approved disease-modifying therapies available.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CIP-137401
Therapeutic Area: Genetic Disease Product Name: CIP-137401
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
AlloMek’s lead drug, CIP-137401, is a macrocyclic MEK kinase inhibitor with excellent pharmacokinetics and a profile optimized for potency and safety. The U.S. FDA has granted orphan-drug designation to CIP-137401, for the treatment of Neurofibromatosis type 1 (NF1).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GENV HEM
Therapeutic Area: Genetic Disease Product Name: GENV HEM
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Geneventiv Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2020
Details:
GeneVentiv plans to move the therapy into the clinic mid-2022. The technology, designated as GENV HEM offers a cure for all types of hemophilia patients with or without inhibitors to their missing clotting factors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PBGM01
Therapeutic Area: Genetic Disease Product Name: PBGM01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The study suggests that delivery of an AAV vector optimized to express b-gal directly into the CSF restored b-gal activity in the brain may be effective in modifying and preventing the devastating effects of the genetic disease GM1.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VY-HTT01
Therapeutic Area: Genetic Disease Product Name: VY-HTT01
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
